SCHEMBL4929453

SCHEMBL4929453

C=C/C=C/C/C=C/CC/C=C/C

nearest known ligand 0.35

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.31
ALDH1A1 P00352 2/20 0.30
MAPT P10636 2/20 0.30
FFAR1 O14842 1/20 0.30
CYP19A1 P11511 1/20 0.30
RXRA P19793 1/20 0.30
PPARG P37231 1/20 0.30
OXER1 Q8TDS5 1/20 0.30
F13A1 P00488 1/20 0.30
THRB P10828 1/20 0.30
PTGS1 P23219 1/20 0.30
FASN P49327 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6199757 1.00 PPARA (0.31) PPARAALDH1A1MAPTFFAR1CYP19A1
SCHEMBL4929461 1.00 PPARA (0.31) PPARAALDH1A1MAPTFFAR1CYP19A1
SCHEMBL6199761 1.00 PPARA (0.31) PPARAALDH1A1MAPTFFAR1CYP19A1
SCHEMBL6202636 0.92 ALDH1A1 (0.38) PPARAALDH1A1MAPTFFAR1CYP19A1
SCHEMBL6202638 0.92 ALDH1A1 (0.38) PPARAALDH1A1MAPTFFAR1CYP19A1
SCHEMBL16103147 0.88 ALOX12 (0.33) PPARAALDH1A1MAPTFFAR1CYP19A1
SCHEMBL16103148 0.88 ALOX12 (0.33) PPARAALDH1A1MAPTFFAR1CYP19A1
SCHEMBL28427560 0.87
SCHEMBL22611958 0.87 LSS (0.33) PPARAPPARG
SCHEMBL22611959 0.87 LSS (0.33) PPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268457-A4 REWORKABLE COMPOSITION OF OXIRANE(S) OR THIIRANE(S)-CONTAINING RESIN AND CURING AGENT LOCTITE CORP (US) 2005-07-20 EP claimed
JP-2003529643-A 2003-10-07 JP claimed
EP-1268457-A1 REWORKABLE COMPOSITION OF OXIRANE(S) OR THIIRANE(S)-CONTAINING RESIN AND CURING AGENT LOCTITE CORPORATION (US) 2003-01-02 EP claimed
WO-2001074798-A1 REWORKABLE COMPOSITION OF OXIRANE(S) OR THIIRANE(S)-CONTAINING RESIN AND CURING AGENT LOCTITE CORPORATION (US) 2001-10-11 WO claimed
EP-3512891-A1 FARNESENE-BASED MACROMONOMERS AND METHODS OF MAKING AND USING THE SAME Fina Technology, Inc. (US) 2019-07-24 EP disclosed
WO-2018052709-A1 FARNESENE-BASED MACROMONOMERS AND METHODS OF MAKING AND USING THE SAME FINA TECHNOLOGY, INC. (US) 2018-03-22 WO disclosed
EP-3071782-A1 MODIFIED HYDROCARBON RESINS AS FLUID LOSS ADDITIVES Georgia-Pacific Chemicals LLC (US) 2016-09-28 EP disclosed
WO-2015077215-A1 MODIFIED HYDROCARBON RESINS AS FLUID LOSS ADDITIVES GEORGIA-PACIFIC CHEMICALS LLC (US) 2015-05-28 WO disclosed
US-20080160116-A1 Compositions and Methods Comprising Zingiber Species HERBALSCIENCE SINGAPORE PTE. LTD (SG) 2008-07-03 US disclosed
US-20070292540-A1 Extracts and Methods Comprising Cinnamon Species HERBALSCIENCE SINGAPORE PTE. LTD. (SG) 2007-12-20 US disclosed
EP-1268457-A4 REWORKABLE COMPOSITION OF OXIRANE(S) OR THIIRANE(S)-CONTAINING RESIN AND CURING AGENT LOCTITE CORP (US) 2005-07-20 EP disclosed
EP-1268457-A1 REWORKABLE COMPOSITION OF OXIRANE(S) OR THIIRANE(S)-CONTAINING RESIN AND CURING AGENT LOCTITE CORPORATION (US) 2003-01-02 EP disclosed
WO-2001074798-A1 REWORKABLE COMPOSITION OF OXIRANE(S) OR THIIRANE(S)-CONTAINING RESIN AND CURING AGENT LOCTITE CORPORATION (US) 2001-10-11 WO disclosed
US-4480123-A Preparation of diacyloxyalkadienes BASF AKTIENGESELLSCHAFT (DE) 1984-10-30 US disclosed
EP-0058236-B1 DIACYLOXYALKADIENES AND THEIR PREPARATION BASF Aktiengesellschaft (DE) 1984-04-25 EP disclosed
EP-0058236-A1 Diacyloxyalkadienes and their preparation BASF Aktiengesellschaft (DE) 1982-08-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080160116-A1 Compositions and Methods Comprising Zingiber Species AGL, SQLE, RBPJ PPARA 473/4885ALDH1A1 1755/4885MAPT 2135/4885
US-20070292540-A1 Extracts and Methods Comprising Cinnamon Species MT-CO2, CA7, CES2 PPARA 1933/4885ALDH1A1 1820/4885MAPT 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.